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Background: Several studies have demonstrated that the presence of the loss-of-function CYP2C19 681G>A polymorphism (also called *2) 
is associated with reduced clopidogrel responsiveness in healthy people and in patients with coronary artery disease. It is not known whether 
CYP2C19*2 loss-of-function polymorphism is related with cardiac events in patients treated with drug-eluting stents (DES). The aim of this study was 
to assess the impact of the CYP2C19*2 polymorphism on cardiac events following PCI performed after pre-treatment with clopidogrel.
Methods: Between March, 2003 and April, 2009, 1,340 patients who were treated with DES and dual-antiplatelet therapy, were enrolled in DES 
cohort and underwent CYP2C19*2 determination. Platelet function was measured with the VerifyNow P2Y12 assay in 550 patients. The primary 
endpoint was a composite of cardiac death, myocardial infarction, stent thrombosis, and coronary revascularization during exposure to clopidogrel 
within 6 months following percutaneous coronary intervention.
Results: Of the patients studied, 707 (53 %) were CYP2C19 wild-type homozygotes (*1/*1), 538 (40 %) were heterozygotes (*1/*2), and 95 (7 
%) were mutant homozygotes (*2/*2). The mean PRU was significantly higher in CYP2C19 mutant homozygotes (*2/*2) versus CYP2C19 wild-type 
homozygotes and heterozygotes (*1/*1, *1/*2) [256±66 in *2/*2, 224±78 in *1/*1 or *1/*2, P=0.015]. The majority of our analyses were 
based on the comparison between mutant homozygotes (*2/*2) and wild-type homozygotes and heterozygotes (*1/*1 or *1/*2) as we assumed 
a recessive model and due to the results of the platelet function assay. The primary endpoint occurred more frequently in mutant homozygotes than 
in wild-type homozygotes and heterozygotes (17 vs. 114 events; hazard ratio [HR] 2.2 [95 % CI 1.2-3.8], P=0.0057), as did revascularization (17 vs. 
103; HR 22.1 [95 % CI 2.0-244.1], P=0.0015).
Conclusions: CYP2C19*2 genetic variant is significantly associated with an increased incidence of cardiac events in patients treated with drug-
eluting stent and dual-antiplatelet therapy and this is mostly due to the increased rate of revascularization.
